Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential

Related Keywords

United States ,Colorado ,Boulder ,Paris ,France General ,France ,United Kingdom ,Northern Ireland ,Craigavon ,London ,City Of ,Great Britain ,American ,Rebeccas Kristeleit ,Patrickj Mahaffy ,Anna Sussman ,Jake Davis ,Jerome Solassol ,Lisa Guiterman ,Breanna Burkart ,Clovis Oncology Inc ,National Cancer Institute ,European Network Of Gynaecological Oncological Trial ,European Society Of Medical Oncology ,National Cancer Research Institute ,Gynecologic Oncology Group ,Nasdaq ,Exchange Commission ,Method Of Administration ,European Union ,American Cancer Society ,Mini Oral ,Cancer Research Institute ,European Society ,Medical Oncology ,Acute Myeloid Leukemia ,Prescribing Information ,Clovis Oncology ,Important Safety ,Product Characteristics ,Preclinical Safety Data ,European Network ,Gynaecological Oncological Trial ,Cancer Institute ,Private Securities Litigation Reform Act ,Annual Report ,Investor Contacts ,Media Contacts ,Clovis ,Ncology ,Rubraca ,Rucaparib ,First ,Line ,Maintenance ,Treatment ,Mproves ,Progression ,Tree ,Survival ,Women ,Dvanced ,Ovarian ,Dancer ,Cross ,Disease ,Risk ,Subgroups ,